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The strong links between (Human Leukocyte Antigen) HLA, infection and autoimmunity
combine to implicate T-cells as primary triggers of autoimmune disease (AD). T-cell
crossreactivity between microbially-derived peptides and self-peptides has been shown
to break tolerance and trigger AD in experimental animal models. Detailed examination of
the potential for T-cell crossreactivity to trigger human AD will require means of predicting
which peptides might be recognised by autoimmune T-cell receptors (TCRs). Recent
developments in high throughput sequencing and bioinformatics mean that it is now
possible to link individual TCRs to specific pathologies for the first time. Deconvolution of
TCR function requires knowledge of TCR specificity. Positional Scanning Combinatorial
Peptide Libraries (PS-CPLs) can be used to predict HLA-restriction and define antigenic
peptides derived from self and pathogen proteins. In silico search of the known
terrestrial proteome with a prediction algorithm that ranks potential antigens in order
of recognition likelihood requires complex, large-scale computations over several days
that are infeasible on a personal computer. We decreased the time required for peptide
searching to under 30min using multiple blocks on graphics processing units (GPUs).
This time-efficient, cost-effective hardware accelerator was used to screen bacterial
and fungal human pathogens for peptide sequences predicted to activate a T-cell
clone, InsB4, that was isolated from a patient with type 1 diabetes and recognised the
insulin B-derived epitope HLVEALYLV in the context of disease-risk allele HLA A∗0201.
InsB4 was shown to kill HLA A∗0201+ human insulin producing β-cells demonstrating
that T-cells with this specificity might contribute to disease. The GPU-accelerated
algorithm and multispecies pathogen proteomic databases were validated to discover
pathogen-derived peptide sequences that acted as super-agonists for the InsB4 T-cell
clone. Peptide-MHC tetramer binding and surface plasmon resonance were used to
confirm that the InsB4 TCR bound to the highest-ranked peptide agonists derived
from infectious bacteria and fungi. Adoption of GPU-accelerated prediction of T-cell
agonists has the capacity to revolutionise our understanding of AD by identifying potential
targets for autoimmune T-cells. This approach has further potential for dissecting T-cell
responses to infectious disease and cancer.
Keywords: type 1 diabetes, T-cell receptor, peptide-HLA, insulin, molecular mimicry, general-purpose computing
on graphics processing units (GP-GPU), Compute Unified Device Architecture (CUDA), Nvidia
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INTRODUCTION
T-cells protect against infections and neoplasms by scanning
the host proteome for anomalies via peptides bound in major
histocompatibility (MHC) molecules at the cell surface. The
peptide specificity of T-cells is determined by the T-cell receptor
(TCR), a highly variable heterodimeric protein generated by
the somatic rearrangement of variable, joining and diversity
gene segments and the quasi-random introduction/deletion of
nucleotides to bestow additional non-germline-derived variation.
Although it is estimated that this process can theoretically
generate ∼1018 different αβ TCRs in human (1) the actual
repertoire possessed by any individual is believed to be of the
order of 108 distinct TCR sequences (2, 3). The major variation
between different TCRs is manifest in the antigen binding
site, composed of six composite complementarity-determining
region (CDR) loops, which contact both the peptide and the
restricting MHC (4, 5). Effective immune coverage requires
that the TCR repertoire must be capable of responding to
almost all foreign peptide sequences that could be presented
by host MHC molecules (1, 6). Unlike the B-cell receptor,
the TCR is fixed and is not susceptible to further alteration
in amino acid sequence or affinity maturation. There is no
time to manufacture new TCRs in the face of an infection,
so it is essential that the receptors on peripheral naïve T-
cells are capable of dealing with any new challenge. Failure
to cover all possible foreign peptide antigens would leave
blind spots in T-cell immunity that pathogens could quickly
evolve to exploit (1). Thus, successful immunity requires that
a repertoire of ∼108 TCRs be capable of responding to a
vastly greater number (>1016) of potential foreign peptides
of a length and sequence capable of being presented by self
MHC molecules (6). This evolutionary challenge is overcome
by a phenomenon termed TCR degeneracy which refers to
the ability of individual TCRs to transmit activation signals
from very large numbers of different peptides bound in a
single MHC molecule (7). The resulting T-cell crossreactivity,
where a single T-cell clonotype can respond to a wide array of
different peptide sequences, is thus an essential feature of T-cell
immunity (1, 6).
Detailed examination of the potential for T-cell crossreactivity
to trigger autoimmune disease (AD) will require means of
predicting which peptides might be recognised by autoimmune
TCRs. Here, we develop tools for this purpose that enabled
the complex calculations involved in screening a wider
pathoproteome to be undertaken by individual researchers
on their own desktop computers. For this purpose, we
focused on the AD type 1 diabetes (T1D) which arises
through immune destruction of insulin-producing β-cells in
the pancreas. T1D is triggered by the direct destruction of
insulin-producing cells by cytotoxic T-cells. Four MHC class
I molecules, human leukocyte antigen (HLA)∗0201 (HLA A2
hereon), HLA A∗24, HLA B∗18, and HLA B∗3906 are risk
factors for T1D (8). Post mortem studies of patients close
to disease onset have showed that numerous CD8 T-cells
present in the characteristic islet mononuclear cell infiltrate
(9). Efficient adoptive transfer of disease in animal models
typically requires CD8 T-cells and disease in such models
is prevented by genetic modifications that abrogate MHC
class I expression (10). Transgenic introduction of the HLA
allele HLA A2 into diabetes-prone non-obese diabetic (NOD)
mice markedly accelerates disease development (11). More
recent studies have described TCRs on activated CD8 T-cells
in patient blood that can recognise β-cell-specific peptides
presented through known disease risk HLA class I alleles
(12–14) and such cells have been placed at the “scene of
the crime” by in situ tetramer staining of insulitic lesions
(15). We previously searched for potential pathogen-derived
peptide ligands for the 1E6 TCR which was isolated from
a type 1 diabetic and shown to exhibit glucose-mediated
killing of human HLA A2+ pancreatic beta cells (12, 14,
16). Two agonist peptides identified were mapped to the
human pathogens Bacteroides fragilis/thetaiotaomicron and
Clostridium asparagiforme demonstrating the potential utility
of this approach for discovery of molecular mimicry (16,
17). These peptide agonists of sequence MVWGPDPLYV
and RQFGPDWIVA, respectively, differed from the wildtype
insulin-derived sequence, ALWGPDPAAA presented at the
cell surface of HLA A2+ human beta cells, and from each
other, at seven of ten positions highlighting the potential
extent of T-cell crossreactivity in this system. Pathogen-derived
agonist peptides were identified using positional scanning
combinatorial peptide library (PS-CPL) data to search the human
pathoproteome (16).
Proteome database searches, in particular those derived
from bacterial genomes, are computationally demanding on
Central Processing Units (CPUs) and therefore of limited
applicability. Here we sought to overcome this limitation
using General-Purpose Graphics Processing Units (GP-GPUs)
to reduce the execution time by a considerable degree. The
great advantage of a using a GP-GPU resides in the ability
to parallelise the task at a massive scale, which allows for
a huge increase in the number of sub-processes carried out
per second (the throughput); even if the total time required
to complete a sub-process (the latency) is somewhat increased,
the net gains can be considerable. Compute Unified Device
Architecture (CUDA), Nvidia’s R© GPU computing platform, is
a free software that allows speed up of compute-intensive
applications by harnessing the power of GPUs for the
parallelisable part of the computation. CUDA has already
been implemented in several bioinformatics tools ranging from
molecular dynamics, sequence alignment, structure prediction,
and spatio-temporal modelling (18–21). Many of these studies
used consumer graphics cards aimed principally at gamers
and costing no more than a few hundred pounds. CUDA
provides a powerful and cost-effective way of accelerating
computations that can be run on desktop setups without
the need to access a high-performance computing (HPC)
server (22). Use of CUDA and standard desktop computation
means source code can be shared among researchers and
run independently, allowing for modifications and greater ease
of use; it also negates increases in wall time that would
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be attributed to the nature of HPC, including job queueing
and hosting.
We previously developed a peptide scoring algorithm that
generates a ranked list of self and corresponding pathogenic viral
peptides predicted to act as T-cell agonists from PS-CPL data
generated with a given T-cell clone (17, 23). Here we extend
this platform to include an expanded human pathoproteome by
building protein databases from pathogenic bacteria and fungi
and by implementing the peptide scoring algorithm into a GPU-
accelerated framework which is suitable in view of the fact that
our algorithm fits the single instruction on multiple data (SIMD)
paradigm (24).
In summary, we present a GPU-accelerated strategy for
epitope discovery and characterisation that uses the CPL-driven
peptide scoring method developed by Szomolay et al. (17) to
rank bacterial and fungal peptides occurring in very large curated
databases in order of likelihood of recognition. Our GPU-
implementation of the scoring algorithm significantly reduces
the computational time and cost and has the potential to
become an efficient application for ligand hunting. C++ is freely
downloadable and can be run on any platform. GPU can be also
included in most personal computers thereby democratising the
approach as a publicly accessible executable, available at https://
github.com/WhalleyT/PICPL. The executable contains both the
C++ and CUDA-versions of the algorithm. It also contains a
test data (a sample of protein sequences and CPL data) that
the user can run on any of the three platforms (Windows,
Linux, MacOS operating systems) and can be downloaded from
the Releases.
MATERIALS AND METHODS
Cell Lines and T-Cells
HLA A2 restricted clone InsB4 that recognises the HLVEALYLV
peptide from the insulin chain (residues 10–18) (25) was grown
from CD8 T-cells purified from a T1D patient using a T-cell
library (26). Clone InsB6 was produced at the same time as
InsB4 and subsequently found to express the same TCR. T-
cell clones were routinely expanded using irradiated (3,000–
3,100 cGy) allogenic PBMCs from three donors and 1µg/mL of
phytohaemaglutinin (PHA) (Alere, Thermo Scientific, Walthan,
MA, USA) in T-cell media made from RPMI-1640 supplemented
with 10% fetal bovine serum (FBS), 2mML glutamine, 100 U/mL
penicillin, 100µg/mL streptomycin, 10mM HEPES 0.5X non-
essential amino acids and 1mM sodium pyruvate (all from Life
Technologies, Carlsband, CA, USA) supplemented with 200 IU
of IL-2 (Aldesleukin, Proleukin, Prometheus, San Diego, CA,
USA) and 25 ng/mL human IL-15 (Peprotech, Rocky Hill, NJ,
USA). T-cells were cultured for 2–4 weeks post-restimulation
before being used for assays. K562 cell lines expressing HLA
A2 and preproinsulin or GAD65 were generated and cultured
as previously described (14, 27). CIRs expressing HLA A2
(28) were grown as suspension cells in R10 medium (RPMI-
1640 with 10% FBS, 2mM L-glutamine, 100 U/mL penicillin
and 100µg/mL streptomycin). Human pancreatic β-cells were
produced as previously described (14, 27). T2 cells (HLA
A2+) were used as peptide presenting cells and cultured as
for K562s.
T-Cell Functional Assays
Functional sensitivity assays using peptides were performed as
previously described (29). T-cells were “rested” overnight in R5
(as for R10 but with 5% FBS) to reduce spontaneous release of
the chemokine, MIP-1β. Individual peptides were synthesised
to >40% purity [GL Biochem (Shanghai) Limited, Shanghai,
China] and titrated for incubation overnight in R5 medium
with the respective clone. Supernatants were harvested for MIP-
1β ELISA using 96 well half area plates and a human MIP-
1β DuoSet ELISA kit from R&D Systems (Minneapolis, MN,
USA). Cytotoxicity assays using chromium 51 (17) or a non-
radioactive europium hydrophilic ligand (14) were performed
as described previously, with minor adjustments: for chromium
release assays, 2,000 target cells were used per well. Data was
initially analysed using GraphPad Prism software to generate
the EC50 of activation (concentration of peptide at 50% of
maximum activation), which was used for further calculations as
described below.
Sizing and Combinatorial Peptide Library
(CPL) Scans
While MHC class I-restricted T-cells can recognise vast
numbers of different peptides, all the strongest agonists tend
to be of a single defined length of between 8 and 14
amino acids (30). The optimal length peptide recognised by
InsB4 T-cells was determined by examining the response to
six random peptide mixtures, X8, X9, X10, X11, X12, and
X13 (where X is any of the 19 proteogenic L-amino acids
excluding cysteine) in 96U well-plates in R5 medium (as for
R10 but with 5% FBS) as for the functional peptide assays
above and described elsewhere (30). MIP-1β was used as a
readout as it is the most sensitive CD8 T-cell functional
indicator (31, 32). Sizing and CPL scan peptide mixtures
were purchased lyophilised at >40% purity (Pepscan Presto
BV, Lelystad, The Netherlands) and stored as 80 or 20mM
DMSO stocks respectively, at −80◦C. Working stocks (10 or
1mM, respectively) were prepared in R0 (as for R10 but
with no FBS), stored at 4◦C, and used in assays at 1 or
0.1mM, respectively.
T-Cell Receptor Sequencing and
Production of Soluble TCR Protein
The TCRs of InsB4 and InsB6 were sequenced in-house using
Sanger sequencing techniques as described previously (33).
Individual TCR chains were expressed in E. coli as soluble
inclusion bodies and refolded as described (34).
Peptide-MHC Multimer Staining
An optimal staining protocol was used for pMHC multimer
staining as previously described (35), involving preincubation
with 50 nM of the protein kinase inhibitor Dasatinib (36),
followed by staining with 0.5 µg of PE conjugated pMHC
tetramer in 50 µL of FACS buffer (2% FBS in PBS),
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then incubation with an anti-PE unconjugated antibody (23).
Subsequently, cells were stained for 5min at RT with 2 µL of
a cell viability stain (Vivid; Life Technologies) that had been
diluted 1:40 using PBS then without washing with anti-CD8-
APC antibody (clone BW135/80, Miltenyi Biotech, Bergisch
Gladbach, Germany). Data acquisition was performed on a
BD FACS Canto II (BD Biosciences, Franklin Lakes, NJ,
US) and analysed using FlowJo Software (TreeStar, Ashland,
OR, US).
Manufacture of Soluble Proteins
Soluble TCR protein and biotinylated pMHCI were
manufactured as previously described (34). Briefly, codon-
optimised InsB4 TCR α and β chains, HLA A2 heavy chain
and β2m chain were generated by Genewiz. All sequences were
confirmed by automated DNA sequencing (Eurofins). TCR
expression constructs were designed with a disulphide linked
construct to produce the soluble domains (variable and constant)
for both the α (residues 1–204) and β chains (residues 1–245)
(34). The HLA A2 heavy chain (residues 1–248) (α1, α2, and α3
domains), tagged, or not tagged with a biotinylation sequence,
and β2m (residues 1–100) were also cloned and used to make
the pMHCI complexes. The TCR α and β chains, the HLA A2
α chain and β2m sequences were inserted into separate pGMT7
expression plasmids under the control of the T7 promoter (5).
Competent Rosetta DE3 E. coli cells were used to produce the
TCR α and β chains, HLA A2 heavy chain and β2m in the
form of inclusion bodies (IBs) using 0.5mM IPTG to induce
expression and protein were chemically refolded as described
previously (37).
Surface Plasmon Resonance
SPR Equilibrium binding analysis was performed using a BIAcore
T200TM equipped with a CM5 sensor chip as previously reported
(38, 39). HLA A2-NLSALGIFST, derived from insulin-like
growth factor 2 mRNA binding protein and recognised by a
different TCR, was used as a negative control on flow cell 1.
SPR kinetic analyses were carried out to determine the KD values
for the TCR, at 25◦C. For all kinetic experiments, approximately
500 RUs of pMHC was coupled to the CM5 sensor chip surface.
The TCR was then injected ten times at serial dilutions, from
a concentration of 407µM, at 30 µl/min. The KD values were
calculated assuming 1:1 Langmuir binding [AB= B∗ABMAX/(KD
+ B)] and the data were analysed using a global fit algorithm
(GraphPad Prism).
GP-GPU Parallelisation of the Peptide
Scoring Algorithm
The code developed by Szomolay et al. (17) was initially written
in Matlab because its ease of use enables rapid prototype
development and testing. As most of the time was spent scoring
amino acid positions in a peptide against a lookup table, and
this process could be performed as a matrix operation, we
optimised the code and were able to obtain a 10-fold speedup
vs. the original prototype algorithm. The code was parallelised
via Matlab’s Parallel Computing Toolbox and scaled up to
multiple hosts in a computational cluster using the Distributed
Computing Server, which allows breaking the protein database
up into sections and sending each section to a different thread.
Results were then collated before the best overall peptide
matches were found. The overhead of parallelisation using
multithreading in Matlab is not significant and accordingly, the
speed gain is virtually linear with respect to the number of
parallel threads.
A more efficient approach to optimising the algorithm is
to use GP-GPU programming, which takes advantage of GPU
architecture that emphasises the parallel execution of very
large numbers of relatively simple processes. The architecture
differences between CPU and GPU are shown in Figure 1A.
One operation is performed on many datasets (e.g., our protein
databases are broken up into 30,000 protein sequences at a
time and a single thread is launched for every protein sequence,
thus analysing the data across multiple GPU blocks). Although
Matlab provides a simple way to develop a prototype as
the Parallel Computing Toolbox supports GP-GPU, substantial
gains could be achieved by rewriting the program in C++.
The code was optimised to minimise bottlenecks in serial
processing and was adapted to run effectively on the GPU.
This meant performing code refactoring to minimise memory
allocation and transfer between the CPU and GPU by unrolling
loops and passing every sequence together as a single one-
dimensional array.
The look-up table and CPL algorithms are shown in
Figure 1B. The CUDA code contains two main functions. The
first function is the generation of the CPL scan data look-up table
(Algorithm 1). In this, for every given amino acid a single thread
was launched. This look-up table is kept in the GPU memory,
where every k-mer is scored by its amino acid composition and
positional score (Algorithm 2) which is done with one thread
for every sequence. Here, the GPU RAM becomes a limiting
factor. In the case of the Nvidia R© Quadro K1200, this is 4GB of
memory, which equates to about 30,000 sequences, along with
the corresponding scoring data required. Once every potential
agonist is scored in every given sequence, the scores are sorted
in descending order based on their agonist likelihood score (3),
a concept introduced in our previous study (17). The 3-score
makes use of the CPL scan data which essentially represents the
recognition preference of a T-cell at each residue position, on
average, over all its agonists. The peptide ranking is performed
with the Thrust library of Bell and Hoberock (40). An in-built
radix sort is used to sort the peptides, as this has been proven to be
well-implemented in the CUDA code. An output file containing
the score, peptide and parent sequence name are returned.
Benchmarking
Benchmarking was performed on four different desktop
implementations of the algorithm: a single core implementation,
a 4 core OpenMP parallel, an 8 core OpenMP implementation
and a CUDA implementation. The CUDA libraries plus
compiler and OpenMP are freely downloadable from https://
developer.nvidia.com/cuda-toolkit and https://www.openmp.
org, respectively.
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FIGURE 1 | GPU-accelerated peptide scoring algorithm. (A) Differences in architecture differences between CPU (left) and GPU (right). Traditionally, computations are
performed by transferring data from global memory to the CPU cores. GPU computing allows for the transfer of data from global memory to device memory, where
the GPU cores can access them. (B) Pseudocode of the two main GPU parallel functions. Algorithm 1 (top) describes the look-up table generation of the peptides
and algorithm 2 (bottom) describes the calculation of the agonist likelihood scores.
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Two benchmarking tests were performed to investigate the
execution time. The first test was undertaken by running each
implementation of the code across databases of varying sizes;
ranging from 106 to 2 × 107 sequences. For consistency, the
database was an artificially generated set of protein sequences
311 amino acids in length (the average protein length found
in the bacterial database). The number of results returned and
the CPL data used were the same in each test. The second test
varied the number of results returned (i.e., the number of top-
scoring peptides), ranging from 100 to 106 against a pathogenic
fungal database consisting of 1.5 × 106 sequences. All code was
benchmarked on a machine running Ubuntu GNOME 16.10,
with a Nvidia R© Quadro K1200 graphics card with 512 cores, an
Intel Core 6700-k processor and 16 GB of memory. All GP-GPU
applications were developed using CUDA, hence were compiled
with the nvcc compiler (v8.0.44). The sequential C++ code
was compiled using the GNU g++ compiler (v5.4.0) with the
C++11 ANSI standard and using the -O1/-O2/-O3 parameter
option. OpenMP parallel code was compiled with the same GNU
compiler, with an OpenMP 4.0 compiler directive.
From Databases to Peptide Universe
The search space of the protein databases represents a tiny
subsection of all possible peptides. For a given 9-mer, there
are 209 (5.1 × 1011) different unique amino acid combinations.
This dwarfs the 16 billion peptides observed in the full
bacterial universe. As well as the database-driven peptide-scoring
algorithm, we have developed an optimised algorithm to score
a selected peptide against the entire peptide universe for given
a CPL data. The code once again leverages the CUDA library
to optimise for speed. The in silico search utilises the GPU’s
architecture to parallelise in 3 dimensions. Therefore, every
possible peptide is generated by means of collecting all sub-
peptides a third of the total peptide size (e.g., for a 9-mer
this would be 8,000 × 3 sets of 3-mers); which are then
combined across all permutations on the GPU. The CUDA- and
C++-version of the algorithm is available at https://github.com/
WhalleyT/PICPL, within the downloadable executable.
RESULTS
T-Cell Clone InsB4 Recognises a bona fide
HLA A2-Restricted Insulin Epitope
Presented at the Surface of Human β-Cells
T-cell clone GD.InsB4 (InsB4 from hereon) was generated
from the blood of a patient with T1D using the T-cell
libraries approach and the putative human insulin β chain10−18
epitope, HLVEALYLV, as previously described (26), with peptide
activation data shown in Figure 2A. This clone was initially
shown to recognise K562 cells transduced with HLA A2 and
preproinsulin (so-called surrogate human β-cells), which were
not killed by a T-cell clone with a different specificity (Figure 2B).
Killing of the surrogate cells by InsB4 was dependent on
expression of preproinsulin as K562 cells transduced HLA
A2 alone or with HLA A2 and GAD65 were not recognised
(Figure 2C). These results show that the HLVEALYLV epitope
can be genuinely processed and presented at the cell surface in
the context of HLA A2. We next demonstrated that InsB4, sister
clone GD.InsB6 (InsB6) and preproinsulin-specific T-cell clone
1E6 (14) could lyse real human pancreatic β-cells (Figure 2D). A
control clone, CMV.1 specific for the CMV pp65-derived epitope
NLVPMVATV, did not kill these pancreatic cells in parallel assays.
We conclude that InsB4 and InsB6 clones, derived from the blood
of a patient with T1D can destroy human pancreatic β-cells and
therefore have capacity to cause T1D. Importantly, these data
represent the first time that the HLVEALYLV peptide has been
confirmed as a genuine human β-cell epitope that is processed
and presented by HLA A2+ pancreatic cells and capable of
resulting in destruction of insulin producing cells.
CPL Screening of T-Cell Clone InsB4
Preference of InsB4 for nonamer peptides was confirmed by
performing a sizing scan using random peptide mixtures of 8,
9, 10, 11, 12, and 13 amino acids in length (Figure 3A). This
sizing scan indicated that the InsB4 T-cell exhibited a strong
preference for peptides of 9 amino acids in length. We next
undertook nonamer combinatorial library screening of the InsB4
clone. MIP1β amounts produced by each of the 180 sublibraries
in the PS-CPL scan is shown in Figure 3B and summarised
as a logo plot in Figure 3C. The “index” glutamic acid sub-
library in position 4 was recognised most strongly, with virtually
no evidence that strong agonists display any other amino acid
residue at this position. The strong preference for a glutamic
acid residue at position 4 suggests that this residue may form
the major TCR contact and, moreover, that the InsB4 TCR might
focus on a precisely delimited hotspot. Sub-libraries with index
peptide residues (i.e., those residues found in the HLVEALYLV
insulin-derived peptide) at positions 1, 5 and 6 were recognised
poorly. Selected sub-libraries at positions 1, 5, 6, 7, and 8
produced more MIP1β than the index sub-library suggesting
that it might be possible to create super-agonist peptides for this
TCR that exhibit greater functional sensitivity than the index
peptide sequence.
Enhanced Screening of Curated Pathogen
Databases Using GPUs
We assembled databases containing protein sequences from
fungi and bacteria. We have previously collated a database of
viral proteomes of species that infect, or might infect, humans
(17). The bacterial proteome database was subdivided into two
pathogenicity classes: category I (species not known to cause,
or which have been proven not to cause, disease in humans
or animals) and category II (species known to infect humans
or animals, including species that can cause human disease).
For a given CPL scan, evaluation of 1,573,341 distinct, proteins
from fungal pathogens and 11,838,978 distinct category I and
11,589,864 distinct category II bacterial proteins took 2, 12,
and 13min, respectively, on the GPU (outputting the 2000
top-scoring peptides in each case). The links to the publicly
available fungal and bacterial databases are provided in the
Supplementary Material.
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FIGURE 2 | T-cell clone InsB4 recognises a genuine HLA A2-restricted, insulin B-derived epitope presented at the surface of human pancreatic β cells. (A) HLA A2
restricted clone InsB4 grown from a patient with type 1 diabetes recognizes the peptide HLVEALYLV from insulin β chain. InsB4 tested with an increasing
concentration of the HLVEALYLV peptide according to the x-axis. Performed in duplicate: overnight incubation and MIP-1β ELISA. Error bars depict SEM.
(B) Surrogate β-cells (K562 transduced with HLA A2 and preproinsulin) were killed by the InsB4 clone. Chromium release cytotoxicity assay at a T-cell to target cell
ratio of 3:1 over 5 h. CMV.1 (pp65 residues 495–503 from CMV) clone used as an irrelevant control. Exogenous index peptides (10−5 M) for each clone were included
as positive controls for killing of the surrogate β-cells. Error bars depict SEM. (C) InsB4 specifically killed surrogate pancreatic β-cells as K562s transduced with HLA
A2 alone or GAD65 (irrelevant protein) and HLA A2 were not recognised. Chromium release cytotoxicity assay at a T-cell to target cell ratio of 3:1 over 5 h. Performed
in duplicate with error bars depicting SEM. Assay performed twice with similar results. (D) InsB4 and sister clone InsB6 (expressing the same TCR) kills real pancreatic
cells. HLA A2 restricted clones 1E6 (preproinsulin (PPI) residues 15–24) and CMV.1 (pp65 residues 495–503 from CMV) were used as positive and negative controls,
respectively. Performed in duplicate with error bars depicting SEM.
GPU Computing Efficiency
We evaluated the training performance of GPU acceleration
on the number of top-ranked peptides and datasets of varying
sizes and compared its performance with other platforms. When
compared with the number of top-ranked peptides, the CUDA
implementation of the algorithm was seemingly unaffected by
the number of top-scoring peptides, unlike the other platforms
(Figure 4A). GPU was superior when tested on datasets of
different sizes and reduced the time to scan datasets by a factor
of ∼4.5 compared to C++ (Figure 4B) thus giving a much
broader search depth. Figure 4C shows the average speed-up for
datasets of different sizes. The CUDA implementation analysed
an average of 18,589.4 sequences per second compared to 4,624.2
sequences and 11,800.6 sequences per second in the serial (C++)
and OpenMP implementations, respectively. This results in a
marked reduction of run time, which is conserved across varying
input data sizes.
The CUDA code was also profiled using the Nvidia R© profiler
(https://developer.nvidia.com/nvidiavisual-profiler) which
demonstrated that the GPU parallelisation removed the scoring
function as the main bottleneck, leaving input/output operations
as the limiting factor on the run time. This was evident from
the Nvidia R© profiler output, which attributed input/output
operations (i.e., reading and writing the files to and from disk)
to take up 28% of the code’s run time. The functional CUDA
code took 11% of the time with the rest being attributed to CPU
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FIGURE 3 | Sizing scan and nonamer combinatorial peptide library screening of InsB4. (A) Sizing scan of the InsB4 clone; overnight activation in duplicate followed by
MIP-1β ELISA. Error bars depict SEM. (B) Overnight activation in duplicate with MIP-1β ELISA. Index peptide residues shown in red. Error bars depict SEM. (C) Logo
plot of normalised MIP-1β expression from data presented in panel B.
dependent operations. This shows that even with substantial
further optimisation, the main time losses would be incurred
with operations that are not easily relegated to the GPU.
Figure 4D compares the speed-up between the GPU and
C++ codes scanned against the entire peptide universe. When
comparing the two extreme cases for the highest (LLIENILFV)
and the lowest (GGCAADCDC) scoring possible peptides, we
observed a significant increase in time. This is because every
time the queried peptide scores lower than a given peptide the
GPU threads must be synchronised and halted while memory is
accessed to add to the ranking value. The highest scoring peptide
was ranked in 82 s, whereas the lowest scoring peptide was ranked
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FIGURE 4 | GPU speed-up compared with C++ and OpenMP. (A) Average total runtime of the peptide scoring algorithm, where the number of returned top-scoring
peptides varied from 100 to 106. (B) Average speed-up across C++ and OpenMP implementations, where the size of the dataset to scan varied from 106 to 2 × 107
sequences. (C) The average rate at which sequences were analysed with CUDA is superior to all the other implementations. (D) Average speed-up by the CUDA and
C++ code to rank theoretical peptides ordered from the highest to the lowest agonist likelihood score.
in 1,117 s leading to >10-fold increase in runtime. Nevertheless,
the GPU-accelerated algorithm performed significantly better
than its serial C++ implementation, which took 16,088 and
16,144 s for the best and worst case, respectively. The index
insulin-derived peptide (HLVEALYLV) ranked at 789,930,969
(still within the top 0.15% of all nonamers) in 85 s.
Validation of the GPU-Accelerated Scoring
Algorithm With Randomly Chosen
Uniformly Distributed Pathogen-Derived
Peptides
We tested the GPU-accelerated strategy by interrogating the
fungal and bacterial pathoproteome for peptides predicted to
activate the autoimmune InsB4 clone. The PS-CPL data depicted
in Figure 3 were used to screen the protein databases compiled
from fungal or bacterial species, as described above. As part
of the database screening, a searching algorithm generates a
hierarchal list of possible agonists by assigning each peptide
with an agonist likelihood score (3) developed in (17). We
previously demonstrated that the cognate peptide for antiviral
or antitumor clones could be identified using PS-CPL data,
pathogenic viral (10,733 proteins) or human self (54,886
proteins) databases and the scoring algorithm using CPU, with
a strong association between the 3-value, and the peptide’s
functional sensitivity to activate the respective clone (17). Here,
our objective was to establish if the GPU-accelerated algorithm
could identify potential agonists from the pathogenic fungi
database (1,573,341 proteins) and the entire pathogenic bacterial
database (23,428,842 proteins).
For the purpose of validation, 72 fungal and 72 bacterial
peptides were chosen, which were uniformly sampled
without repetition and whose 3-values spanned ∼6 orders
of magnitude, thus placing 12 peptides in six “bins,” with
each bin representing an order of magnitude. To achieve a
sufficiently large span of unique 3-values for sampling, the
top 3 × 105 fungal and top 5 × 106 bacterial peptides were
ranked by the searching algorithm based on the CPL data.
This was only feasible by using multiple cores on GPUs,
which increased the speed of peptide identification from
>1 day to under 3 and 11min, for the fungal and bacterial
sequences, respectively.
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Each peptide was tested for functional sensitivity in titration
assays, with InsB4 activation quantified by MIP-1β ELISA
(Figures 5, 6). For the fungal protein-derived peptides it was
evident that the most potent agonists resided in Bin 1 with
7 sequences being more potent than the index insulin10−18
sequence (Figure 5). Average ligand functional sensitivity
decreased through Bins 2–5 such that activation was only
observed with 4/12 peptides in the 5th Bin. Results were similar
for peptides identified from the much larger bacterial protein
database (Figures 6, 7A) except the greater number of overall
peptides resulted in more being found that were of higher
functional sensitivity than the index insulin10−18 sequence.
The most potent sequences found were LLVENIPLF (Bin 1),
IILEGILIL from (Bin 2), and ILLEDGMLL (Bin 3). None of
the peptides in Bin 6 acted as agonists of the InsB4 T-cell
(Figures 6, 7A).
Overall, it was apparent that peptides that scored as being
most likely to be seen by InsB4 were indeed better agonists
for InsB4, with fewer peptides being recognised when moving
from Bin 1 to Bin 6, for both the fungal and bacterial peptides
(Figure 7A). In order to make comprehensive comparisons
between the 144 peptides, the pEC50 (defined as –log10 EC50)
of InsB4 activation for every peptide was compared to that
of the HLVEALYLV index (pEC
index
50
), giving each peptide a
relative functional sensitivity (1pEC50 = pEC50 – pEC
index
50
).
We examined the statistical association between the agonist
likelihood score3 and the relative functional sensitivity1pEC50
for all 144 randomly chosen peptides using both the Spearman’s
and Pearson’s correlation coefficient (Figure 7B). For the fungal
peptides, Spearman correlation was 0.42 (significant at the 0.5%
level) and the Pearson correlation was 0.48 (significant at the
0.1% level). For the bacterial peptides, Spearman correlation was
0.36 (significant at the 0.1% level) and the Pearson correlation
was 0.39 (significant at the 0.1% level). These results demonstrate
that the CPL-driven database searching can accurately identify
peptides derived from cellular organisms that were recognised by
an autoimmune T-cell clone.
Pathogen-Derived Peptides Can Act as
Super-Agonist Ligands for an Insulin
B-Specific T-Cell Clone
Our CPL-based peptide searching algorithm identified several
peptides derived from bacterial and fungal proteins that shared
a very low sequence homology with the index insulin-derived
peptide but were recognised by the InsB4 T-cell clone with higher
functional sensitivity. Whereas, the above approach randomly
sampled peptides from the bacterial and fungal databases, we
next explored the top scoring peptides from each database
and functionally tested 20 peptides. As shown in Figure 8,
the top 5 most potent fungal InsB4 ligands were peptides
derived from Candida albicans (MIVENVPLL), Saccharomyces
cerevisiae (LIIENAPLI), Aspergillus niger (LLVENWPLL),
Mucor circinelloides (MLVEGVLLA), and Sporothrix schenckii
(MIVEGFLLL). As shown in Figure 9, all 20 bacterial peptides
for InsB4 were recognised (19 gave unambiguous EC50 values),
with 7 of the peptides eliciting greater activation from InsB4 than
the index HLVEALYLV insulin-derived peptide. Furthermore,
peptides from Streptococcus caballi (IIIEGILFV) andHelicobacter
pylori (MLLENGLLA) acted as super agonists of InsB4. These
data strongly suggest that the InsB4 TCR can bind to pathogen-
derived peptides with higher affinity than with the index
HLVEALYLV sequence that can mediate destruction of human
pancreatic β-cells.
In order to formally prove enhanced TCR binding we
examined pMHC tetramer staining and ligand interaction with
soluble InsB4 TCR by SPR. The InsB4 T-cell clone stained
well with tetramers made with HLA A2-MIVENVPLL (C.
albicans) and HLA A2-MLLENGLLA (H. pylori) (Figure 10A).
In contrast staining with the index peptide, insulin-derived HLA
A2-HLVEALYLV tetramer was very weak. Peptide-HLA tetramer
staining intensity is known to correlate with TCR affinity for
the cognate ligand (29). Autoimmune TCRs are known to stain
poorly with cognate tetramer (35, 41), so this weak staining was
not unexpected. Interaction between the InsB4 TCR and HLA
A2-HLVEALYLV was too weak to measure by SPR. In contrast,
C. albicans-derived HLA A2-MIVENVPLL andH. pylori-derived
HLA A2-MLLENGLLA antigens bound with a KD of 60.7 and
168.5µM, respectively, confirming that these peptides engage
the TCR within an affinity range capable of triggering T-cell
activation (Figure 10B). Attempts to gather structural data of the
InsB4 TCR in complex with a cognate antigen failed as we were
unable to grow crystals of this TCR, despite multiple attempts.
DISCUSSION
There is a pressing need for efficient computational methodology
for prediction of peptide mimics and super-agonists for
therapeutically relevant T-cell clones. Here, we first validated a
human insulin β chain10−18 epitope HLVEALYLV using T1D
patient-derived T-cell clone InsB4 and showed that this T-cell
could kill human pancreatic β-cells. These data represent the
first time that the HLVEALYLV peptide has been confirmed
as a naturally processed β-cell-presented epitope. Recognition
patterns of random peptide mixtures of 8, 9, 10, 11, 12, and
13 amino acids in length clearly showed that the InsB4 T-cell
preferred nonamer peptides. In order to investigate the peptide
degeneracy profile of InsB4 we performed a nonamer PS-CPL
screen. InsB4 demonstrated a clear preference for a glutamic acid
residue at position 4 strongly suggesting that this residue acts
as the primary TCR contact within the peptide. In support of
this notion, this residue was prominent in all the super-agonist
peptides we extracted from the pathoproteome.
In order to determine whether the InsB4 T-cell could
cross-react with pathogen-derived peptides we turned to
computational screening of PS-CPL data. In silico searching of
the known terrestrial proteome with our algorithm previously
developed using Matlab (17) takes several days on an HPC
server. We reduced the time for these searches to under
30min using GP-GPU allowing this approach to be run on a
desktop or laptop computer. The search algorithm generates
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FIGURE 5 | Recognition of 72 randomly chosen and uniformly distributed fungal peptides by the InsB4 T-cell clone. Each panel shows results of MIP-1β assay,
indicating activation of T-cell clone InsB4 by 12 peptides and the index HLVEALYLV peptide (shown as a bold red line). InsB4 was incubated overnight with the
indicated peptides and MIP-1β released into the supernatants quantified by ELISA. Bins 1–5 were performed in the same assay with Bin 6 performed in a separate
experiment hence the different EC50 values for the index peptide. EC50 for each peptide (M) is displayed in the tables. NR, no T-cell response. The mean pEC50 for
each bin is plotted in Figure 7A.
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FIGURE 6 | Recognition of 72 randomly chosen and uniformly distributed bacterial peptides by the InsB4 T-cell clone. Each panel shows results of MIP-1β assay,
indicating activation of T-cell clone InsB4 by 12 peptides and the index HLVEALYLV peptide (shown as a bold red line). InsB4 was incubated overnight with the
indicated peptides and MIP-1β released into the supernatants quantified by ELISA. Bins 1-5 were performed in the same assay with Bin 6 performed in a separate
experiment hence the different EC50 values for the index peptide. EC50 for each peptide (M) is displayed in the tables. NR, no T-cell response. The mean pEC50 for
each bin is plotted in Figure 7A.
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FIGURE 7 | The agonist likelihood score is able to identify fungal and bacterial peptide agonists. (A) pEC50 values of InsB4 clone activation towards randomly
sampled peptides shown in Figures 5, 6. NR, no T-cell response. Solid bars depict the mean and error bars the SEM. (B) Scatter plot of relative functional sensitivity
(1pEC50) for the 72 fungal and 72 bacterial randomly sampled peptides shown in Figures 5, 6 vs. agonist likelihood score.
a list of potential agonists by assigning to each peptide an
agonist likelihood score (17). Testing with 144 peptides selected
uniformly across a logarithmic scale of the lambda score from
the fungal and bacterial pathoproteome with values spanning
∼6 orders of magnitude demonstrated that the CPL-driven
database searching could accurately identify peptides derived
from cellular organisms that were recognised by an autoimmune
T-cell clone. Functional testing of 20 high scoring peptides
from the new bacterial and fungal databases showed that 20/20
and 18/20 acted as agonists of the InsB4 insulin-specific T-cell
clone. Furthermore, 7/20 and 12/20 sequences predicted from the
bacterial and fungal databases weremore potent agonists than the
HLVEALYLV index sequence. In theory, if presented in vivo, such
super-agonist peptides might have the capacity to break tolerance
to trigger disease. Importantly, one bacterial and one fungal
peptide derived fromH. pylori and C. albicans, respectively, were
selected to demonstrate conclusively that they could engage the
InsB4 autoimmune TCR as peptide-MHC tetramers and by SPR.
Interestingly, several recent studies have shown an increased
rate of H. pylori infection in T1D patients (42–45) leading to
suggestions that it may be a disease trigger; however, it is also
possible that T1D might render patients more susceptible to H.
pylori infection. Similarly, T1D has also been linked with C.
albicans at the time of diagnosis (46) but diabetes is known to
predispose individuals to fungal infections (47) so the direction
of any link is still in question.
The resemblance between epitopes derived from microbial
and host proteins leading to crossreactivity of T-cells in the host
has been termed molecular mimicry (48, 49) and is believed to be
a major mechanism by which autoimmune diseases are triggered
(50, 51). Indeed, T-cell crossreactivity between microbially-
derived peptides and self-peptides can induce autoimmunity
in experimental animal models (52–54). Recent studies have
confirmed that TCRs are capable of recognising large numbers
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FIGURE 8 | InsB4 recognizes fungal peptides with increased sensitivity relative to index insulin peptide. The 20 top-scoring peptides from fungal species were tested
overnight for activation on InsB4 by MIP-1β ELISA. The likelihood scores and EC50 of peptide (M) activation are shown. Putative proteins are the product of predicted
open reading frames from the genome sequence of the species indicated. NR, no T-cell response. Bold EC50 more potent than the index peptide. Amino acid
residues that are the same for each fungal peptide and the insulin index peptide (HLVEALYLV) are underlined.
Frontiers in Immunology | www.frontiersin.org 14 February 2020 | Volume 11 | Article 296
Whalley et al. Accelerated T-Cell Epitope Prediction
FIGURE 9 | InsB4 recognizes bacterial peptides with increased sensitivity relative to index insulin peptide. The 20 top-scoring peptides from category II (i.e.,
confirmed pathogenic) bacterial species were tested overnight for activation on InsB4 by MIP-1β ELISA. The likelihood scores and EC50 of peptide (M) activation are
shown. Putative proteins are the product of predicted open reading frames from the genome sequence of the species indicated. Bold EC50 more potent than the
index peptide. ∼ = ambiguous EC50 based on GraphPad Prism software analysis. Amino acid residues that are the same for each bacterial peptide and the insulin
index peptide (HLVEALYLV) are underlined.
of different individual peptides in the context of a single MHC
molecule (7, 55, 56). Several mechanisms for TCR promiscuity
have been suggested that include; macrolevel changes in
peptide binding register, alterations in TCR crossing angle on
peptide-MHC (pMHC), TCR CDR loop flexibility, and residue
focused “hotspot” binding (1). Evidence for these mechanisms
is emerging and points to further unanticipated molecular
flexibility that can extend the range of peptides recognised via
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FIGURE 10 | Pathogen-derived peptide ligands bind to the InsB4 TCR. (A) Optimised pMHC tetramer staining of the InsB4 T-cell clone with HLA A2-HLVEALYLV
(insulin), HLA A2-MLLENGLLA (H. pylori) and HLA A2-MIVENVPLL (C. albicans) epitopes. (B) SPR binding data of the interaction between the InsB4 TCR and HLA
A2-MIVENVPLL and HLA A2-MLLENGLLA. Binding with the index HLA A2-HLVEALYLV peptide was too weak to measure.
individual TCRs. The TCR can interact with different pMHCs
using a common (55, 57–60), or a highly divergent binding mode
(61). The structure of TCR CDR loops are known to differ in
ligated and unligated TCR crystal structures suggesting that these
loops are flexible and might be capable of binding to different
peptides in different ways (59, 62). However, it is worth noting
that a recent study found large conformational differences of
up to 5 Å in individual CDR loops in different crystals of the
same unligated TCR, suggesting that crystal structures may only
offer an artefactual indication of TCR flexibility due to lattice
packing and crystallisation conditions (63). Two recent studies
have described extensive peptide crossreactivity as the result of
constrained interactions with peptide hotspots in MHC class
I and class II-restricted peptides (16, 55). More recent studies
have shown that heretofore unanticipated rearrangements in
the peptide and presenting MHC protein can extend the range
of ligands that can be recognised (64, 65). The potential
consequences of widespread T-cell crossreactivity are profound
and range from heterologous immunity, where an individual T-
cell clone can target more than one pathogen via a single TCR,
to crossreactivity between pathogen-derived and self-peptides
[reviewed in (1)].
While the combined computational-experimental approach
presented in this study can be used to discover potential
infectious triggers for autoimmune disease. Further work will
be required to reveal if any of the potential infection-derived
peptides found by our work are genuinely presented to T-cells
in vivo. Moreover, this combined computational-experimental
approach also has the potential to be used to discover potent
peptide agonists of any T-cell clone for use in TCR-optimised
peptide skewing of the repertoire of T-cells (TOPSORT) (66) and
to rank the agonist potential of D-amino acid peptides (67). The
GPU-accelerated strategy has not only surpassed the previous
framework (17) in terms of speed, cost-, and power-efficiency,
but it has also demonstrated its robustness by addressing
the theoretical peptide ranking problem. In sum, GPU-based
computing is practical and within reach of users with a desk-top
computer; as such, we expect that it will findmultiple applications
in other computationally demanding areas of immunology such
as immune phenotyping and antigen receptor analysis.
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